Daclizumab
How it works: Calming and slowing immune cells →
Zinbryta
EU: WithdrawnUS: FDA approved 2016
- Molecule type
- Antibody
- Mechanism (ChEMBL)
- Interleukin-2 receptor inhibitor
- Targets
- Interleukin-2 receptor
Approvals
Other regulatory events
- Withdrawn · Zinbryta27 March 2018 Source
Safety communications
- EMA referral · 9 June 2017
Zinbryta Source
Most-reported side effects (FDA reports)
Reports to the FDA's adverse event system (FAERS) show what people and doctors reported while taking the medicine. They do not prove the medicine caused it, and they are not rates.
1,742 reports in total, 1,703 marked serious.
- Transplant dysfunction408
- Transplant rejection407
- Alopecia406
- Acne367
- Ovarian cyst365
- Pneumonia229
- Drug ineffective188
- Cytomegalovirus infection164
- Condition aggravated163
- Pain159
Trials
Key trials
Large trials with a reported result on their main goal.
- Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus
Completed · Phase 3 · Relapsing MS · Met its main goal
Other trials (13)
Completed small trials, dose-finding studies and trials in other diseases.
- Efficacy and Safety of Daclizumab in Participants With RRMS Switching
Terminated · Phase 3 · Relapsing MS · Stopped
- ZEUS - ZINBRYTA real world use study in Germany
Stopped · Not a drug-phase study · Relapsing MS · Stopped
- Long-Term Extension Study in Participants With Multiple Sclerosis Who
Terminated · Phase 3 · Relapsing MS · Stopped
- An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab
Completed · Phase 3 · Relapsing MS · Results posted, not judged
- Safety and Efficacy Extension Study of Daclizumab High Yield Process (
Completed · Phase 2 · Relapsing MS · Results posted, not judged
- Safety and Efficacy Extension Study of Daclizumab High Yield Process (
Completed · Phase 2 · Relapsing MS · Main goal was not benefit
- An Extension Study to Evaluate the Safety and Efficacy of DAC HYP in S
Completed · Phase 2 · Relapsing MS
- Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) t
Completed · Phase 2 · Relapsing MS · Met its main goal
- Multicentre, double-blind, placebo-controlled, dose-ranging study to d
Terminated · Phase 2 · Relapsing MS · Stopped
- A Phase II, Randomized, Double-Blinded, Placebo-Controlled, Multi-Cent
Completed · Phase 2 · Relapsing MS
For information only, not medical advice. Talk to your neurologist before changing treatment.
Hypotheses involving this medicine
Loading hypotheses…
Loading reviews and guidelines…
Lab studies
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…